Tedisamil dihydrochloride | 132523-84-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂螺癸烷衍生物
• 英文名称: Tedisamil dihydrochloride
• 英文别名: 3,7-bis(cyclopropylmethyl)spiro[3,7-diazabicyclo[3.3.1]nonane-9,1'-cyclopentane];dihydrochloride
• CAS: 132523-84-3
• 化学式: C19H34Cl2N2
• 分子量: 361.4
• InChiKey: NXXZICGFHYJPGE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.07
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  6.5
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  替地沙米 、 盐酸 在 异丙醇 、 丙酮 作用下， 以 异丙醇 为溶剂， 以2 g of tedisamil dihydrochloride were obtained的产率得到Tedisamil dihydrochloride
  参考文献：
  名称：

  Crystalline fumaric acid salts of 9,9-alkylene-3,7-diazabicyclononane

  摘要：

  1.5 富马酸盐是指N,N'-二低烷基取代的9,9-烷基-3,7-二氮杂双环[3.3.1]壬烷的盐，以及一种获得它们在化学计量纯度和几乎不吸湿形式的方法。

  公开号：

  US05324732A1

文献信息

• Liquid pharmaceutical formulations containing 3,7-diazabicyclo[3,3,1] nonane compounds and methods of treatment relating to anti-arrhythmic events
  申请人：Solvay Pharmaceuticals GmbH

  公开号：US20040152716A1

  公开（公告）日：2004-08-05

  The present invention relates to the use of 3,7-diazabicyclo[3,3,1]nonane compounds, preferably of 9,9-alkylene-3,7-diazabicyclo[3,3,1]nonane compounds, and most preferably to the use of tedisamil, and the physiologically acceptable acid addition salts and/or solvates thereof, in the form of a liquid pharmaceutical preparation for the treatment and/or inhibition of anti-arrhythmic events in human patients, preferably in conversion of recent onset of atrial fibrillation or flutter to normal sinus rhythm in humans. Furthermore, the invention concerns related methods of treatment and pharmaceutical products.

  本发明涉及3,7-二氮杂双环[3,3,1]壬烷化合物，最好是9,9-亚烷基-3,7-二氮杂双环[3,3,1&rsqb；壬烷化合物，最优选的是泰迪沙米及其生理学上可接受的酸加成盐和/或溶解物，以液体药物制剂的形式用于治疗和/或抑制人类患者的抗心律失常事件，最好是将人类近期发生的心房颤动或扑动转化为正常窦性心律。此外，本发明还涉及相关的治疗方法和药物产品。
• Method of treating or inhibiting anti-arrhythmic events in male human patients
  申请人：Cautreels Werner

  公开号：US20050054667A1

  公开（公告）日：2005-03-10

  A method of treating or inhibiting anti-arrhythmic events in male human patients by administering to a patient in need thereof a pharmaceutically effective amount of a 3,7-diazabicyclo[3,3,1]nonane compound, preferably a 9,9-alkylene-3,7-diazabicyclo[3,3,1]nonane compound, and especially preferably tedisamil, or a physiologically acceptable acid addition salt thereof or a solvate thereof. The method is particularly useful in converting recent onset of atrial fibrillation (Afib) or flutter to normal sinus rhythm (NSR) in male human patients.

  一种治疗或抑制男性人类患者抗心律失常事件的方法，向有需要的患者施用药学有效量的3,7-二氮杂双环[3,3,1]壬烷化合物，优选9,9-亚烷基-3,7-二氮杂双环[3,3,1]壬烷化合物，尤其优选泰迪沙米，或其生理学上可接受的酸加成盐或其溶液。该方法尤其适用于将男性患者近期发生的心房颤动（Afib）或扑动转为正常窦性心律（NSR）。
• Liquid pharmaceutical formulations containing 3.7-diazabicyclo[3,3,1]nonane compounds and methods of treatment relating to arrhythmic events
  申请人：Straub Matthias

  公开号：US20050261300A1

  公开（公告）日：2005-11-24

  A method of using 3,7-diazabicyclo[3,3,1]nonane compounds, preferably of 9,9-alkylene-3,7-diazabicyclo[3,3,1]nonane compounds, and most preferably to the use of tedisamil, and the physiologically acceptable acid addition salts and/or solvates thereof, in the form of a liquid pharmaceutical preparation for the treatment and/or inhibition of arrhythmic events in human patients, preferably in conversion of recent onset of atrial fibrillation or flutter to normal sinus rhythm in humans, as well as related methods and pharmaceutical products or packages.

  一种使用 3,7-二氮杂双环[3,3,1]壬烷化合物的方法，优选 9,9-亚烷基-3,7-二氮杂双环[3,3,1]壬烷化合物，最优选使用 Tedisamil 及其生理上可接受的酸加成盐和/或溶液、以液体药物制剂的形式，用于治疗和/或抑制人类患者的心律失常事件，最好是将人类近期发生的心房颤动或扑动转为正常窦性心律，以及相关方法和药品或包装。
• LIQUID PHARMACEUTICAL FORMULATIONS CONTAINING 3,7-DIAZABICYCLO[3,3,1] NONANES FOR TREATING ANTI-ARRHYTHMIC EVENTS
  申请人：Abbott Products GmbH

  公开号：EP1565239B1

  公开（公告）日：2011-03-16
• LIQUID PHARMACEUTICAL FORMULATIONS CONTAINING 3,7-DIAZABICYCLO'3,3,1! NONANES FOR TREATING ANTI-ARRHYTHMIC EVENTS
  申请人：Solvay Pharmaceuticals GmbH

  公开号：EP1565239A2

  公开（公告）日：2005-08-24